

Press Release

FUJIFILM purchases Hitachi Diagnostic Imaging to lead health prevention and diagnostics in Europe

FUJIFILM Healthcare Europe results from the 1.3 billion Euro acquisition and integration of this division in FUJIFILM's healthcare systems activity

7 September 2021

Japanese multinational FUJIFILM launched FUJIFILM Healthcare Europe in July as a result of the acquisition and integration of Japanese company Hitachi Diagnostic Imaging in March 2021 for 1.3 billion Euros. A full, integrated range of diagnostic products and services was presented at the launch, including CT (Computed Tomography), MRI (Magnetic Resonance Imaging), X-Ray, AI (Artificial Intelligence), PACS (Picture Archiving and Communication System), women's health, IVD (In Vitro Diagnostics), endoscopy and ultrasound systems.

On 1 September, **Fujifilm Portugal** will take full control of FUJIFILM Healthcare's operations and solutions in Portugal under the same management and coordinated by the same team.

This investment reflects FUJIFILM's commitment to its European Medical Systems business area, in the Japanese multinational's growth strategy aimed at becoming a leader in the European health prevention and diagnostics industry. The combined ranges of products and services from both companies, which have been separate until now, strengthens Fujifilm's global capacity to offer a comprehensive solution to meet the most diverse clinical needs.

This new FUJIFILM brand will also have a scientific and clinical research element in the health prevention and diagnostics areas through protocols to be established with educational, research and healthcare institutions.

Through FUJIFILM Healthcare Europe, the company intends to significantly expand the diagnostics and prevention areas globally as one of the group's growth

drivers, aiming to achieve a turnover of 6.6 billion Euros within the next three years; growth of over 50% compared to the fiscal year ending on March 2020.

Highlights from the new portfolio supporting this potential:

- 1) **FUJIFILM Healthcare Europe**'s high image quality Computed Tomography (CT) and Magnetic Resonance Imaging (MRI), combined with Fujifilm's AI technological platform REiLi and SYNAPSE 3D, which supports post-processing, offering Radiology departments a low dose and full support solution, from image acquisition to advanced diagnostics.
- 2) In ultrasound, a superior, diversified Fujifilm offer for various clinical specialties, including Gynaecology, Surgery, and Urology, as well as a wide range of Radiology products.
- 3) Expanded application and technical support and service across the complete portfolio of Fujifilm medical products.

"We have worked hard to achieve this important milestone for Fujifilm and its future development. Today we are stronger together, and our goal is to maximise these new comprehensive and complete portfolio synergies. Our goal is to position ourselves as a market leader and number one comprehensive partner for the Healthcare community in Europe in the field of prevention and diagnosis" says Toshi Iida, President and Managing Director of FUJIFILM Europe.

"We bring to Fujifilm many decades of experience in the market, alongside a strong and comprehensive product portfolio. The two organisations complement each other perfectly, and I am excited for the service and support we can offer together with a new combined team that is ready to embrace new challenges and great adventures in the future. Together we are stronger." said Jean-Luc Budillon, President and COO, FUJIFILM Healthcare Europe.

"It is an honour as well as a great responsibility for Fujifilm Portugal, as the first subsidiary of the group in Europe to achieve the full integration of FUJIFILM Healthcare's solutions into the company's Medical Systems division, to offer, as of today, a global and comprehensive image diagnostics solution combined with excellent service," said Pedro Mesquita, CEO of FUJIFILM Portugal and Spain.

About Fujifilm in Europe

Fujifilm operates over 50 group companies and branches in Europe and employs approximately 4,500 people engaged in R&D, manufacturing, sales and service, with FUJIFILM Europe GmbH, located in Düsseldorf, Germany, operating as the strategic headquarters for the region. Throughout Europe, Fujifilm entities serve a range of industries including medical technology, biopharmaceuticals, electronic materials, industrial products, chemicals, graphic systems, optical devices, data storage and all aspects of photography. Over the last 20 years, the company has more intensively focused on healthcare - from diagnosis to prevention and treatment. Today, Fujifilm in Europe provides the entire spectrum of patient care, in addition to research, development and manufacturing in advanced therapies, gene therapies and vaccines, as well as providing cell culture media and regenerative medicine solutions. For more information, please visit: [fujifilm.com](https://www.fujifilm.com)

About FUJIFILM Holdings Corporation

FUJIFILM Holdings Corporation, located in Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the fiscal year ended March 31, 2021, the company had global revenues of Euro 16,7 billion, at an exchange rate of 131,6 yen to the Euro. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit: [holdings.fujifilm.com](https://www.holdings.fujifilm.com)